China Expects $71 Million in Gene Therapy Project Kickoffs in First-Half 2022
China Expects $71 Million in Gene Therapy Project Kickoffs in First-Half 2022
Attachment: gene
BEIJING--March 23, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--So far, three kinds of gene/cell therapy drugs in China have attained a China Food and Drug Administration (CFDA) license: a recombinant human p53 adenovirus injection; a recombinant human adenovirus type-5 injection; and a CAR-T cell therapy product (developed by FosunKite Bio).
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Jacobs Solutions Has Hand in $75 Billion Worth of U.S. Projects
- Contractor DPR Construction at Work on $8.8 Billion in U.S. Projects
- Pharma-Biotech Dominates New England's $19.6 Billion of Projects Under Cons...
- China's WuXi Biologics Snaps up Second European Pharma Plant
- WuXi Snaps Up Bayer's Final Drug Manufacturing Plant in Germany
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
